Publications in collaboration with researchers from Maastricht University (18)

2024

  1. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

    Alzheimer's and Dementia

2023

  1. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  2. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  3. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Multimodal Biomarker Discovery Dataset

    Frontiers in Aging Neuroscience, Vol. 14

  2. Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation

    Molecular Psychiatry, Vol. 27, Núm. 4, pp. 1990-1999

2021

  1. Replication study of plasma proteins relating to Alzheimer's pathology

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464

  2. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

  3. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  2. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938

  2. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

    Alzheimer's and Dementia, Vol. 15, Núm. 5, pp. 644-654

  3. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488

  4. Inflammatory biomarkers in Alzheimer's disease plasma

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 776-787

  5. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 742-753

  6. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 817-827